Antibody manufacture in transgenic animals and comparisons with other systems

Current Opinion in Biotechnology

Volumn 13, Issue 6, 2002, Pages 625-629

  Houdebine, Louis Marie ^a  

^a CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD6 ANTIGEN; DNA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINE; PRION PROTEIN; RECOMBINANT ANTIBODY;

ANTIBODY ENGINEERING; ANTIBODY ISOLATION; ANTIGEN BINDING; BACTERIUM; BACULOVIRUS; CELL LINE; CELL MEDIATED CYTOTOXICITY; GENE ISOLATION; GENETIC TRANSFECTION; HUMAN; IN VIVO STUDY; LYMPHOCYTE; MILK; NONHUMAN; PLANT CELL; PRIORITY JOURNAL; REVIEW; TRANSGENIC ANIMAL; YEAST; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; COMPARATIVE STUDY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MOUSE; PROTEIN ENGINEERING; TRANSGENIC PLANT;

ANIMALIA; BACTERIA (MICROORGANISMS); INSECTA; UNIDENTIFIED BACULOVIRUS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; HUMANS; MICE; MILK; PLANTS, GENETICALLY MODIFIED; PROTEIN ENGINEERING;

EID: 0036900866     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(02)00362-2     Document Type: Review

References (57)

1. Fletcher M.C., Kuderova A., Cygler M., Lee J.S. Creation of a ribonuclease abzyme through site-directed mutagenesis. Nat Biotechnol. 16:1998;1065-1067.
2. Harris B. Exploiting antibody-based technologies to manage environmental pollution. Trends Biotechnol. 17:1999;290-295.
3. Simoes E.A. Respiratory syncytial virus infection. Lancet. 354:1999;847-852.
4. Casadevall A. Antibodies for defense against biological attack. Nat Biotechnol. 20:2002;114.
5. Corthesy B. Recombinant immunoglobulin A: powerful tools for fundamental and applied research. Trends Biotechnol. 20:2002;65-71.
6. Casadevall A. Antibody-mediated protection against intracellular pathogens. Trends Microbiol. 6:1998;102-107.
7. Gura T. Therapeutic antibodies: magic bullets hit the target. Nature. 417:2002;584-586. Summarizing recent data, the author reports arguments favouring the idea that the therapeutic use of recombinant antibodies is greatly increasing with the result that production capacity is becoming quite insufficient.
8. Ferrantelli F., Ruprecht R.M. Neutralizing antibodies against HIV - back in the major leagues? Curr Opin Immunol. 14:2002;495-502.
9. Quadri S.M., Lai J., Mohammadpour H., Vriesendorp H.M., Williams J.R. Assessment of radiolabeled stabilized F(ab′)2 fragments of monoclonal antiferritin in nude mouse model. J Nucl Med. 34:1993;2152-2159.
10. Webber D. Lymphoma Mabs rivalry continues. Nat Biotechnol. 16:1998;1000-1001.
11. Baluna R., Coleman E., Jones C., Ghetie V., Vitetta E.S. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp Cell Res. 258:2000;417-424.
12. Poncet P., Panczak A., Goupy C., Gustafsson K., Blanpied C., Chavanel G., Hirsch R., Hirsch F. Antifection: an antibody-mediated method to introduce genes into lymphoid cells in vitro and in vivo. Gene Ther. 3:1996;731-738.
13. Hudson P.J. Recombinant antibody fragments. Curr Opin Biotechnol. 9:1998;395-402.
14. Rader C., Ritter G., Nathan S., Elia M., Gout I., Jungbluth A.A., Cohen L.S., Welt S., Old L.J., Barbas C.F. III. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem. 275:2000;13668-13676.
15. Huls G.A., Heijnen I.A., Cuomo M.E., Koningsberger J.C., Wiegman L., Boel E., van der Vuurst de Vries A.R., Loyson S.A., Helfrich W., van Berge Henegouwen G.P., et al. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol. 17:1999;276-281.
16. Lo D., Pursel V., Linton P.J., Sandgren E., Behringer R., Rexroad C., Palmiter R.D., Brinster R.L. Expression of mouse IgA by transgenic mice, pigs and sheep. Eur J Immunol. 21:1991;1001-1006.
17. Weidle U.H., Lenz H., Brem G. Genes encoding a mouse monoclonal antibody are expressed in transgenic mice, rabbits and pigs. Gene. 98:1991;185-191.
18. Lorenzen N., Cupit P.M., Einer-Jensen K., Lorenzen E., Ahrens P., Secombes C.J., Cunningham C. Immunoprophylaxis in fish by injection of mouse antibody genes. Nat Biotechnol. 18:2000;1177-1180.
19. Heppner F.L., Musahl C., Arrighi I., Klein M.A., Rulicke T., Oesch B., Zinkernagel R.M., Kalinke U., Aguzzi A. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science. 294:2001;178-182.
20. Jakobovits A. Production of fully human antibodies by transgenic mice. Curr Opin Biotechnol. 6:1995;561-566.
21. Mendez M.J., Green L.L., Corvalan J.R., Jia X.C., Maynard-Currie C.E., Yang X.D., Gallo M.L., Louie D.M., Lee D.V., Erickson K.L., et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 15:1997;146-156.
22. Tomizuka K., Yoshida H., Uejima H., Kugoh H., Sato K., Ohguma A., Hayasaka M., Hanaoka K., Oshimura M., Ishida I. Functional expression and germline transmission of a human chromosome fragment in chimaeric mice. Nat Genet. 16:1997;133-143.
23. Kost T.A., Condreay J.P. Recombinant baculoviruses as expression vectors for insect and mammalian cells. Curr Opin Biotechnol. 10:1999;428-433.
24. Andersen D.C., Krummen L. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol. 13:2002;117-123. The authors describe possible modifications of the CHO cell culture method to optimize its capacity to produce recombinant antibodies at an industrial scale.
25. Berdoz J., Blanc C.T., Reinhardt M., Kraehenbuhl J.P., Corthesy B. In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells. Proc Natl Acad Sci USA. 96:1999;29-34.
26. Andersson R, Mynahan R: The protein production challenge: in vivo. The Business and Medicine Report 2001, May 1-5.The authors are Arthur D Little consultants who compared the capacity of the different production systems for recombinant antibodies. They also evaluated the total potency of these systems and the amplitude of the market in the coming years.
27. Larrick J.W., Yu L., Naftzger C., Jaiswal S., Wycoff K. Production of secretory IgA antibodies in plants. Biomol Eng. 18:2001;87-94.
28. Stoger E., Sack M., Fischer R., Christou P. Plantibodies: applications, advantages and bottlenecks. Curr Opin Biotechnol. 13:2002;161-166.
29. Houdebine L.M. Transgenic animal bioreactors. Transgenic Res. 9:2000;305-320.
30. Pollock D.P., Kutzko J.P., Birck-Wilson E., Williams J.L., Echelard Y., Meade H.M. Transgenic milk as a method for the production of recombinant antibodies. J Immunol Methods. 231:1999;147-157. The authors have prepared more than 10 recombinant antibodies in mouse or goat milk. This article summarizes the different problems they faced and how they achieved success.
31. Wright A., Morrison S.L. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol. 15:1997;26-32.
32. Faye L, Lerouge P, Gomord V: Perfect mammalian glycoproteins in plants come of age. In Molecular Farming. Edited by Toutant JP, Balazs E. INRA Editions Paris: Springer-Verlag, Berlin; 2001, 187-195.
33. Chargelegue D., Vine N.D., Van Dolleweerd C.J., Drake P.M., Ma J.K. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res. 9:2000;187-194.
34. Ma J.K., Hikmat B.Y., Wycoff K., Vine N.D., Chargelegue D., Yu L., Hein M.B., Lehner T. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med. 4:1998;601-606.
35. Bouquin T., Thomsen M., Nielsen L.K., Green T.H., Mundy J., Dziegie M.H. Human anti-rhesus D IgG1 antibody produced in transgenic plants. Transgenic Res. 11:2002;115-122.
36. Lubon H. Transgenic animal bioreactors in biotechnology and production of blood proteins. Biotechnol Annu Rev. 4:1998;1-54.
37. Raju T.S., Briggs J.B., Borge S.M., Jones A.J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology. 10:2000;477-486.
38. Umana P., Jean-Mairet J., Moudry R., Amstutz H., Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 17:1999;176-180. In this study, it is reported that CHO cells overexpressing β(1,4)-N- acetylglucoseaminyltransferase III produce recombinant antibodies harbouring the bisecting GlcNac monosaccharide. These antibodies induce ADCC. The same approach could be extended to transgenic animals to obtain fully active antibodies in milk.
39. Weikert S., Papac D., Briggs J., Cowfer D., Tom S., Gawlitzek M., Lofgren J., Mehta S., Chisholm V., Modi N., et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol. 17:1999;1116-1121. CHO cell lines overexpressing human β1,4-galactosyltransferase or α2,3-sialyltransferase secrete a higher proportion of recombinant antibodies containing sialic acid. This approach could be extended to transgenic animals in order to improve glycosylation of recombination antibodies secreted in milk.
40. Sola I., Castilla J., Pintado B., Sanchez-Morgado J.M., Whitelaw C.B., Clark A.J., Enjuanes L. Transgenic mice secreting coronavirus neutralizing antibodies into the milk. J Virol. 72:1998;3762-3772.
41. Castilla J., Pintado B., Sola I., Sanchez-Morgado J.M., Enjuanes L. Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk. Nat Biotechnol. 16:1998;349-354.
42. Limonta J., Pedraza A., Rodriguez A., Freyre F.M., Barral A.M., Castro F.O., Lleonart R., Gracia C.A., Gavilondo J.V., de la Fuente J. Production of active anti-CD6 mouse/human chimeric antibodies in the milk of transgenic mice. Immunotechnology. 1:1995;107-113.
43. Van Kuik-Romeiln P., De Groot N., Hooijberg E., De Boer H. Expression of a functional mouse-human chimeric anti-CD19 antibody in the milk of transgenic mice. Transgenic Res. 9:2000;155-159.
44. Newton D.L., Pollock D., DiTullio P., Echelard Y., Harvey M., Wilburn B., Williams J., Hoogenboom H.R., Raus J.C., Meade H.M., Rybak S.M. Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice. J Immunol Methods. 231:1999;159-167.
45. Houdebine LM, Attal J, Vilotte JL: Vector design for transgene expression. In Transgenic Animal Technology, Edn 2nd. Edited by Pinkert CA. Academic Press: London, UK; 2002, in press.
46. Recillas-Targa F., Pikaart M.J., Burgess-Beusse B., Bell A.C., Litt M.D., West A.G., Gaszner M., Felsenfeld G. Position-effect protection and enhancer blocking by the chicken β-globin insulator are separable activities. Proc Natl Acad Sci USA. 99:2002;6883-6888.
47. Taboit-Dameron F., Malassagne B., Viglietta C., Puissant C., Leroux-Coyau M., Chereau C., Attal J., Weill B., Houdebine L.M. Association of the 5′HS4 sequence of the chicken β-globin locus control region with human EF1 α gene promoter induces ubiquitous and high expression of human CD55 and CD59 cDNAs in transgenic rabbits. Transgenic Res. 8:1999;223-235.
48. Fujiwara Y., Miwa M., Takahashi R., Hirabayashi M., Suzuki T., Ueda M. Position-independent and high-level expression of human α-lactalbumin in the milk of transgenic rats carrying a 210-kb YAC DNA. Mol Reprod Dev. 47:1997;157-163.
49. Stinnakre M.G., Soulier S., Schibler L., Lepourry L., Mercier J.C., Vilotte J.L. Position-independent and copy-number-related expression of a goat bacterial artificial chromosome α-lactalbumin gene in transgenic mice. Biochem J. 339:1999;33-36.
50. Rival-Gervier S., Viglietta C., Maeder C., Attal J., Houdebine L.M. Position-independent and tissue-specific expression of porcine whey acidic protein gene from a bacterial artificial chromosome in transgenic mice. Mol Reprod Dev. 63:2002;161-167.
51. Chadd H.E., Chamow S.M. Therapeutic antibody expression technology. Curr Opin Biotechnol. 12:2001;188-194.
52. Gavin WG: DVM: The future transgenics. Regulatory Affairs Focus 2001, May 13-18.The author gives comments on the official guidelines that need to be followed when producing recombinant proteins in milk. With reference to his own experience, the author considers that this regulatory process is not a limitation to the use of milk as a source of recombinant proteins.
53. Houdebine L.M. Transgenic animal bioreactors. Transgenic Research. 9:2000;305-320.
54. Harvey A.J., Speksnijder G., Baugh L.R., Morris J.A., Ivarie R. Expression of exogenous protein in the egg white of transgenic chickens. Nat Biotechnol. 20:2002;396-399.
55. Kuroiwa Y., Kasinathan P., Choi Y.J., Naeem R., Tomizuka K., Sullivan E.J., Knott J.G., Duteau A., Goldsby R.A., Osborne B.A., Ishida I., Robl J.M. Cloned transchromosomic calves producing human immunoglobulin. Nat Biotechnol. 20:2002;889-894.
56. Echelard Y., Meade H. Toward a new cash cow. Nat Biotechnol. 20:2002;881-882.
57. Dove A. Uncorking the biomanufacturing bottleneck. Nat Biotechnol. 20:2002;777-779.